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Summary 
By reverse  transcriptase  polymerase chain reaction on messenger RNA from human polymor- 
phonuclear  cells,  we have isolated a sequence identical  to  the cDNA  coding for intracellular 
interleukin 1 receptor antagonist (iclL-lra), but containing an additional in-frame 63-bp sequence 
located three codons downstream of the translation  start of iclL-lra.  This additional sequence 
is inserted between the first and second exon of the intracellular  form,  the latter  of which is 
colinear with part of the first exon of the secreted form of IL-lra.  The additional  sequence is 
coded by an extra exon located 2 kb downstream the first iclL-lra-specific exon. The complementary 
DNA sequence of the alternatively  spliced form of iclL-lra  shows that  the predicted protein 
differs  from classical  iclL-lra in the NH2 terminus  by insertion of a leaderless  sequence of 21 
amino  acids rich in glycine and glutamic  acid residues.  Transcripts  coding for this new form 
of iclL-lra were detected in activated fibroblasts,  keratinocytes, and at low levels in myelomonocytic 
cells. The recombinant protein expressed in COS cells had an apparent molecular mass in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis of 25 kD compared to 22 kD of classical iclL- 
lra, and was mostly intracellular. The ability of this new form of iclL-lra to inhibit IL-1 activity, 
in terms of induction of E-selectin and human immunodeficiency virus replication, was comparable 
to that of classical iclL-lra. We propose to refer to this new form of iclL-lra as iclL-lra type II. 
I 
L-lc~ and IL-1B are pleiotropic cytokines exerting  a va- 
riety of effects on different tissues (1). The potent inflam- 
matory effects of IL-1 are under strict physiological control. 
IL-1  synthesis is inhibited  by antiinflammatory  cytokines, 
prostaglandins,  and glucocorticoids  (1).  IL-1 receptor type 
II (IL-1RII) is a nonsignaling,  IL-l-binding  molecule that 
acts as a regulated decoy target for IL-1 (2-4). Finally, IL-1 
is the only cytokine for which a polypeptide receptor an- 
tagonist (IL-lra) has been described (5-7). The existence of 
multiple levels of inhibition  of IL-1 points to the necessity 
for a tight  control  of this  mediator. 
IL-lra is a polypeptide molecule that binds IL-1R type I 
(IL-1RI) and, less avidly, IL-1KII without any agonistic ac- 
tivity (8). IL-lra is induced in different cell types, including 
mononuclear phagocytes, polymorphonuclear cells, and fibro- 
blasts by IgG, cytokines, and bacterial products (8).  As an 
IL-1  competitor,  IL-lra  may represent  a potentially useful 
pharmacological  tool in inflammatory  diseases  (1). 
Two molecular forms of IL-lra have been identified and 
cloned. Secreted IL-lra (slL-lra) contains a classical 25-amino 
acid leader peptide giving a mature protein of 152 amino acids 
(6, 7). Intracellular IL-lra (iclL-lra) has no leader sequence, 
thus predicting that this protein remains intraceUular  (9). slL- 
lra and iclL-lra are generated from the same gene. iclL-lra 
transcripts originate from an alternative start site and splicing 
of an  alternative  first exon into an internal  splice acceptor 
site located in the first exon of slL-lra (9). The predicted pro- 
teins are thus identical except in their NH2 end,  in which 
the first  21  amino  acids  of slL-lra  are substituted by four 
amino acids in iclL-lra. Expression of transcripts coding for 
slL-lra and iclL-lra is differentially regulated (9). slL-lra and 
iclL-la have similar capacity to inhibit IL-1 activity (10). The 
biological significance of iclL-lra  is  still  unclear. 
Here, we report the identification, cloning, and functional 
characterization of a new molecular form of iclL-lra gener- 
ated by the expression of a new 63-bp exon located 2 kb down- 
stream the first intracellular  specific exon. We propose to refer 
to this new form of iclL-lra as iclL-lra type II (iclL-lralI). 
Materials and Methods 
Cells.  Human circulating  PMN, monocytes, and endothelial 
cells (EC) were obtained and cultured as described  in previous reports 
(11). Chronically infected U1 cells were cultured as described (12). 
COS cells were cultivated in DMEM medium  (Gibco, Glasgow, 
Scotland) with 10% FCS (Hyclone Laboratories, Logan, UT) and 
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FCS (Hyclone). Human keratinocyte cultures were kindly provided 
by Prof. M. L. Tenchini (Dept. of Biology and Genetics for Med- 
ical Sciences, University of Milano, Milano, Italy). 
Stimuli.  Human recombinant (hr) IL-1B (3  x  107 U/rag) was 
from Domp~ (L 'Aquila, Italy). hrTNF-ol (6.6  x  107 U/mg) was 
from BASF (Knoll, Germany). LPS (LPS B from Escherichia coli 
055:B5) was purchased from Difco Laboratories (Detroit, MI). PMA 
was from Sigma hrlblot and hrIb4 (5  x  107 U/mg) were from 
Immunex (Seattle,  WA). hrlL-10 (107 U/mg) was from DNAX 
(Palo Alto,  CA).  Hrlb13  was  from Sanofi  Elf Bio Recherches 
(Labege, France). IgG for clinical use was from Sandoz (Basel, Swit- 
zerland) and was aggregated by heating at 63~  for 30 min. 
Reverse Transcriptase PCR.  Total RNA was  extracted by the 
guanidinium thiocyanate method (13). RT-PCK was performed as 
described  (14).  Oligonucleotides were obtained  from Duotech 
(Milano, haly). The sequences ofoligos used to selectively amplify 
iclblra were identical to those previously described (9). In partic- 
ular, we used oligos GM397 (indicated here as IRA 1) and GM368 
(IRA 4). For iclIMraII amplification, we used IRA 4 and IRA 5 
(5' CTGACTTGTATGAAGAAGGAGGTGG  3'), which specifically 
recognizes the extra exon described here included in the icIblraII 
sequence (Fig.  1). The oligonucleotides for/$-actin amplification 
were 5' GCGCTCGTCGTCGACAACGG 3' and 5' GATAGACAA- 
CGTACATGGCTG 3'. Amplified products were run through a 1% 
ethidium  bromide-stained  agarose  gel  and  transferred  onto  a 
nitrocellulose filter (Stratagene,  La Jolla, CA); hybridization was 
carried out according to standard protocols (D), with a previously 
labeled oligonucleotide specific for icIblraII (5' GACTCAAAG- 
GAGACGATCTGCCG 3') (13). Amplification products were sub- 
cloned (TA cloning system;  InVitrogen, San Diego, CA) and se- 
quenced by the chain termination method. Analysis of icIL-lraII 
sequence was performed with the Proexplore software package (Ox- 
ford Molecular Ltd., Oxford, UK). 
PCR with Genomic DNA.  Genomic DNA was extracted fol- 
lowing standard protocols (13) from human circulating monocytes. 
0.5 #g of genomic DNA was amplified at 94~  for 1 min, 60~ 
for 1 min, and 70~  for 4 min. We used IRA 1 (see above), IRA 
9 (5 TTTGAGTCAGCATTGTCTTCA 3), IRA 7 (5 CTGACT- 
TGTATGAAGAAGGAGGTGG  3), and IRA 10, which is identical 
to B(BSI.1)  (15). 
Expression of icILlra Products in COS Cells.  The cDNAs con- 
taining 32 bp of the 5' untranslated region, the complete open 
reading frame,  and  6 bp  (including  the  stop codon) of the 3'- 
untranslated region of both the icIL-lraI  and icIblraII were ob- 
tained by RT-PCR with oligonucleotides IRA 4 and IRA 5 as 
detailed above, ligated back into the pSG5 expression vector, and 
transfected into COS cells. After 2 d, culture-concentrated super- 
natants and sonicated cell lysates were examined by ELISA or im- 
munoblotting as detailed below. 
Identification oflmmunoreactive IL1ra.  A commercial ELISA assay 
(Amersham, Buckingamshire, UK), which identifies both sIL-lra 
and icIblra, was used. For Western blot analysis two polyclonal 
antisera (rabbit, generous gift from Dr. C. Dinarello, Tufts Univer- 
sity, Boston, MA; and goat, Amersham) were used. COS cells ly- 
sates samples and supernatants were run on 12.5% SDS-PAGE and 
then blotted onto a nitrocellulose filter (Stratagene). Immunoreac- 
tire protein bands were revealed by a chemiluminescence-based  pro- 
cedure (ECL detection; Amersham) according to the manufacturer's 
instructions. 
ILl Responses.  Confluent EC cultivated in 96-well plates (Falcon 
Labware, Oxnard, CA) were incubated for 30 min with an amount 
of transfected COS cell lysate (see above) corresponding to 25-100 
ng of recombinant Iblra (either icIL-lraI or icIL-lraII),  as assessed 
by a specific  ELISA assay (Amersham). As a control, an equal amount 
of COS lysate obtained from mock-transfected ceils was used in 
parallel. Next, 0.1-1 ng/ml human recombinant Ibl/~ was added 
to the cultures for 6 h. The detection of E-selectin expression was 
made with an ELISA assay on adherent EC with the anti-E-selectin 
mAb BB1C-E2 (courtesy of Dr. A. Gearing, British Biotechnology, 
Oxford, UK) as primary Ab and a rabbit anti-mouse Ig antiserum 
conjugated with horseradish peroxidase as a secondary Ab. Optical 
density quantification was determined with a spectrophotometer 
(Flow,  Milano,  Italy) at a 405-nm wavelength. 
Chronically infected U1  cells  (2  x  10  s cells/ml  in  24-weU 
plates; Falcon) were stimulated with IblB (0.01-10 ng/ml) in the 
presence or absence of 100-fold excess of icIblraI or icIblralI or 
an equal amount of COS lysate obtained from mock-transfected 
cells. Cell culture supernatants were harvested 72 and 144 h after 
stimulation and tested for the presence  of Mg + +-dependent RT 
activity as a parameter of virion production (12). 
Results 
Identification of a New Isoform of iclL-Ira.  Specific oligo- 
nucleotide primers were designed (Fig. 1, IRA1 and IRA4) 
to  amplify the entire coding  sequence of icIL-lra (Fig.  1) 
by  RT-PCK.  Amplified  products  from  human  polymor- 
phonudear ceUs were subcloned and sequenced. In addition 
to the previously known  sequence of icIL-lra,  we isolated 
a number of clones whose sequences were identical to the 
published icIL-lra coding sequence, with the notable excep- 
tion of an extra 63-bp sequence between nucleotides 132 and 
133 of the iclL-lra sequence. Given the described exon-in- 
tron boundaries of icIL-lra (8), the extra sequence is inserted 
between the first leaderless exon of iclL-lra and its second 
exon, which corresponds to the 3' half of the first exon of 
slL-lra (Fig. 1). The predicted amino acid sequence is shown 
in Fig.  1.  The putative new protein (thereafter referred to 
as icIL-lraII) has the first three amino acids at the NH2 end 
in common with the classical icIL-lra (therefore referred to 
as iclL-lraI), followed by a new sequence of 21 amino acids. 
The rest of the two proteins are identical. The complete icIL- 
lraII consists of 180 amino acids. The most striking charac- 
teristic of the inserted extra sequence is the presence of seven 
glycine residues, six of which are consecutive. Glycine residues 
are flanked on both sides by glutamic acid residues.  Com- 
puter analysis of iclL-lraII-specific sequence was performed, 
and a number of genes showed a similarity to the icIL-lraII 
specific exon (not shown).  The overall hydrophilic pattern 
of icIL-lraII is similar to that of icIL-lraI, lacking a hydro- 
phobic leader peptide  at  the NH2 terminus  (not  shown). 
Genomic Organization of lL-lra Gene.  The icIL-lraI first 
exon had been previously localized ,,o9.6 kb upstream of the 
slL-lra first exon (reference 8 and Fig. 2), but sequence in- 
formation was available for a 6-kb region located immedi- 
ately upstream of the slL-lra first exon (15, 16). This intronic 
sequence did not contain our putative extra exon.  We hy- 
pothesized, therefore, that the putative extra exon might be 
localized in the remaining 3.5-kb genomic sequence not yet 
available (15,  16). We therefore designed the IRA 10 oligo- 
nucleotide, which is colinear with the most 5' sequence of 
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GAATTCCGGGCTGCAGTCACAGAATGGAAATCTGCAGAGGCCTCCGCAGTCACCTAATCACTCTCCTCCTCTTCCTGTTCCATTCAG  MetGluIleCysArgGlyLeuArgSerHisLeuIleThrLeuLeuLeuPheLeuPheHisSer 
Intracellular IL-Ira type I 
IRA1 
CA~CCTCCTGTCCTAT~.GGCCCTCCCCATGGCTTTAG 
MetAlaLeu 
Intracellular IL-Ira type II 
IRA1  IRA5 
CAGAAGACCTCCTGTC  CTATGAGGC  C  C  TC  C  C  C  ATG  GCTTTAGC  TGAC  TTGTATGAAGAAGGAGGTGGAGGAGGAGGAGAAGGTGAAGACAATGCTGACTCAA  GG 
MetAlaLeuAl  aAspLeuTyrGluGluGlyGlyGlyGlyGlyGlyGluGlyGluAspAsnAlaAspSerLys 
Common IL-Ira sequence 
AGACGATCTGCCGACCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTATC TGAGGAACAACCAACTAGTTGCTGGATACTTGCAA 
GluThrI  l  eCysArgProSerGlyArgLysSe  r  Se  r  Ly  sMetGl  nAl  a  PheArgI  i  e  TrpAspValAs  nG  1  n  Ly  sThr  PheTyr  LeuArgAsnAsnGlnLeuValAl  aGly  TyrLeuGl  n 
GGACCAAATGTCAATTTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCATGGAGGGAAGATGTGCCTGTCCTGTGTCAAGTCTGGTGATGAGACC 
GlyProAsnValAsnLeuGluGluLy  s  I  i  eAspVa  i  Va  1P  r  ol  l  eGl  uP  roHi  sAlaLeuPheLeuGl  y  I  i  e  H  i  s  G  i  y  Gl  y  LysMet  CysLeuSerCysValLysSerGlyAspGluThr 
AGACTCCAGCTGGAGGCAGTTAACATCACTGACCTGAGCGAGAACAGAAAGCAGGACAAGCGCTTCGCCTTCATCCGCTCAGACAGTGGCCCCACCACCAGTTTTGAGTCTGCCGCCTGC 
ArgLeuGl  nLeuGluAlaValAsnI  l  eThrAspLeuSe  r  Gl  uAsnArgLysGl  nAspLysArgPheAlaPhe  I  i  eArgSerAspSerGlyProThrThrSerPheGluSerAlaAlaCys 
C  CCGGTTGGTTCCTCTGCACAGCGATGGAAGCTGACCAGCCCGTCAGCCTC~CCAATATGCCTGACGAAGGCGTCATGGTCACCAAATTCTACTT~CAGGAGGACGAGTAGTAC 
P  roGlyTrpPheLeuCy  s  ThrAlaMetGl  uAl  aAspG  1  nProVal  S  er  LeuThrAs  nMe  t  ProAspG  I  uGl  yValMe  t  Va  1Thr  Ly  s  PheTyrPheGilnGluAspGlu* 
IRA 4 
Figure  1.  eDNA sequence  and predicted protein sequence  of iclL-lralI compared to classical iclLlra (iclL-lraI)  and slblra. The upper part of the 
figure shows the eDNA and protein sequences specific for slLolra, iclblraI, and iclL-lralI. The lower part of the figure shows the sequence in common 
among the three forms of Iblra. For clarity,  the eDNA sequence  of iclL-lra  starts from nucleotide 91 of the published 5' untranslated sequence,  and 
only 6 bp of the 3' untranslated sequence  are reported. The common IL-lra  sequence  starts with the internal acceptor site located in the first  exon 
of slDlra, corresponding to nucleotide 133 of the complete iclL-lraI sequence and to nucleotide 88 of the complete sllclra sequence. The PCR primers 
(see text) are indicated with arrows.  The asterisk indicates the stop codon. The sequence  is available from EMBL/Gene Bank/DDBJ under accession 
number X84348. 
INTRON SIZE (kb)  2.1  7.5  1.8  1.4  1.5 
EXON SIZE (bp)  --  -- 
132  63  130  89  113  1358 
/__  /___ 
IRA9  IRA10 
.._X  ._.X 
IRA1  IRA7 
IclL-lral 
iclL-1 rail 
slL-lra 
Figure  2.  Organization of the human IL- 
lra gene. The boxes represent the exons (the 
size is not representative of the actual length 
in basepairs),  icI, the first exon of the intra- 
cellular  form; iclI,  the new exon described 
in this paper; sl, the first exon of the soluble 
form; 2, 3, and 4, the 3' exons. The charac- 
terized isoforms described so far are schemat- 
ically  represented  in  the  lower  part.  The 
lengths of the exons and introns are indicated 
above. The PCR primers (see text) are indi- 
cated with arrows. 
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RNAs from 8387 fibroblasts  (.4), monocytes  (B), polymorphonuclear  cells 
(C), and keratinocytes  (D) treated  with different  stimuli  as indicated  below 
were reverse-transcribed.  Each cDNA synthesis  reaction  was then divided 
in two aliquots, one of which was amplified  with oligonucleotides  IRA 
5 (forward)  and IRA 4 (backward) (see Fig. 1) for detection of icI1:lralI 
transcripts, and the other with fl-actin-specific  oligonucleotides.  Amplified 
products were then examined  through an ethidium  bromide-stained  agarose 
gel and the signals from monocytes and polymorphonuclear  cells were 
amplified  by Southern  blotting (B and C). Amplified  products  corresponding 
to fl-actin are on the left part of each panel and amplified  products corre- 
sponding to icI1:lralI (on the right) panel are indicated  by an arrow. (A) 
8387 fibroblasts were incubated with medium (lane I), 10 ng/ml PMA 
(lane 2), 50 ng/ml LPS (lane  3), 500 U/ml TNF-cx (lane 4), and 10 ng/ml 
IL-lcx (lane 5). (B) Monocytes  were incubated with medium (lane 1), 10 
ng/ml I1_-4 (lane  2), 10 ng/ml IL-10 (lane  3), 10 ng/ml I1:13 (lane 4), 100 
ng/ml LPS (lane 5), and 200 #g/ml aggregated IgG (lane 6). (C) Poly- 
morphonuclear  cells  were incubated  with medium (lane I), 10 ng/ml II.-4 
(lane 2), 10 ng/ml 1I:10 (lane 3), 10 ng/ml II.-13 (lane  4), 100 ng/ml LPS 
(lane 5), and 200 #g/ml aggregated IgG (lane 6). Keratinocytes,  (panel 
D) were unstimulated (1). 
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the known intronic sequence (16),  and IRA 1 oligonucleo- 
tide, whose sequence is contained within the first iclL-lra 
exon. The genomic 3.5-kb fragment was amplified, cloned, 
and sequenced. As expected, the corresponding 63-nucleotide 
sequence was found at a distance of 2.1 kb downstream rela- 
tive to the first iclL-lraI exon and was flanked by the exon- 
intron junction consensus AG and GT nucleotides. To fur- 
ther  verify the exact localization of the extra  exon,  other 
oligonucleotides were constructed  (IRA 9  and IRA 7;  see 
Fig. 2), and the size of the amplified fragments was consis- 
tent with the indicated localization (data not  shown). 
Expression of  iclL-ra in Different Cell Types.  To identify iclL- 
lralI transcripts, RT-PCK analysis was performed with IRA 
4 and IRA 5 oligonucleotides (Fig.  1). As shown in Fig. 3 
A, a signal specific  for iclL-lralI is not present in quiescent 
(lane 1) or LPS-stimulated (lane 3) 8387 fibroblasts, but was 
dearly induced upon exposure to PMA (lane 2), TNF-cx (lane 
4),  and IL-lol (lane 5).  In parallel experiments,  these same 
stimuli were equally effective for the induction of the iclL- 
lraI expression (data not shown and reference 17). When ex- 
pression in monocytes was studied (Fig. 3 B), a distinct band 
for iclL-lralI was evident after hybridization with a specific 
oligonucleotide and was induced by LPS treatment (lane 5). 
In  parallel  experiments,  IL-4,  IL-10,  IL-13,  LPS,  and  ag- 
gregated IgG were equally effective in inducing iclL-lraI ex- 
pression  (data not shown and reference  14).  Expression  of 
iclL-lralI was also studied in polymorphonuclear cells,  ei- 
ther unstimulated or exposed to several stimuli including IL-4, 
IL-10, IL-13, LPS, and aggregated IgG. A band was present 
after hybridization with a specific  oligonucleotide and was 
not modified much by different stimuli (Fig. 3  C).  Under 
identical conditions, we had reported the induction of iclL- 
lraI upon exposure of polymorphonuclear cells to IL-13 (14). 
Finally, keratinocytes, which express  iclL-lraI  (9),  showed 
high levels of iclL-lralI mRNA. The specificity of amplified 
products from PMA-treated fibroblasts and LPS-stimulated 
monocytes was confirmed by subcloning and sequencing (not 
shown). All in all, these results indicate that iclL-lralI is ex- 
pressed in a variety of cell types, with a pattern of induction 
that is to some extent different from that of iclL-lraI and 
slL-lra. 
Expression  of Recombinant  iclL-lralI and Biological Activ- 
ity.  COS cells were transfected with the cDNA sequences 
coding for iclL-lralI or iclL-lraI, and cell lysates and super- 
natants were examined in Western blots.  The rabbit  poly- 
clonal antisera used in these experiments recognized equally 
well iclL-lralI and iclL-lraI, which were found mostly in 
cell lysate (data not shown). Recombinant iclL-lraI migrated 
as a major 22-kD  band,  whereas iclL-lralI showed a mass 
of ~25  kD  (Fig.  4). 
Recombinant iclL-lraI and iclL-lralI were examined for 
their ability to inhibit IL-l-induced E-selectin expression on 
endothelial cells.  Lysates from mock-transfected COS  cells 
did not significantly reduce IL-1 activity, iclL-lralI had no 
agonistic activity. As shown in Fig. 5 (representative of three 
experiments), recombinant iclL-lralI inhibited E-selectin in- 
duction in a dose-dependent fashion. The inhibitory activity 
oficlL-lralI was similar to that exerted by iclL-lraI expressed 
A New Isoform of the Interleukin 1 Receptor Antagonist Figure 4.  Western  blot analysis  of 
recombinant iclblrall.  Cell lysates 
from COS cells transfected  with the 
cDNAs coding for iclL-lraI  (lane 2), 
iclL-lralI (lane  3), or with the empty 
vector (lane 1) were examined  by im- 
munoblotting with anti-ILlra rab- 
bit polyclonal antiserum. Molecular 
weight standards are indicated. 
under the same experimental conditions. Recombinant iclL- 
lraI and iclL-lralI were also tested for their ability to inhibit 
IL-1-induced HIV expression in U1 cells. Induction of HIV 
expression from U1 cells was not observed at any tested con- 
centration (up to 1/zg/ml) of iclL-lralI, iclL-lralI suppressed 
IL-13-dependent  triggering of HIV expression in U1  cells 
(data  not  shown). 
Discussion 
In this report, we describe a new molecular form of IL- 
lra, termed iclL-lralI, iclL-lralI is identical to iclL-lraI, ex- 
cept for an additional stretch of 21 amino acids located within 
the NH2-terminal portion of the molecule.  This iclL-lralI 
sequence is encoded by a novel exon located within the 9.6-kb 
region between the first and second exon of iclL-lraI. Thus, 
by differential splicing,  three isoforms of IL-lra are gener- 
ated and their expression is, to some extent, differentially regu- 
lated in different cell types and/or  in response to different 
stimuli. 
iclL-lralI  is biologically active, in that  the molecule ex- 
pressed in  COS cells inhibit  IL-1/3  activity with  ef~ciency 
comparable to that oficlL-lraI. It has previously been reported 
that iclL-lraI and slL-lra have similar capacity to inhibit IL-1 
(10).  The actual biological  significance of the intracellular 
isoforms of IL-lra and of their differential expression remains 
unclear. They may represent reservoirs of IL-lra, to be released 
upon cell death or to inhibit putative intracellular actions of 
IL-1. 
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Figure 5.  Effects  of recombinant  iclL-lraI  and iclL-lralI  on IL-l-induced 
expression of E-selectin on ECs. ECs were treated with 0.1 (A) or 1 (B) 
ng/ml human IL-1B  in the presence or absence of 0.1-100 ng/ml recom- 
binant iclL-lraI,  iclIAralI, or equivalent  amounts of  COS lysates  obtained 
from cells transfected  with an empty vector (mock). After a 6-h incuba- 
tion, endothelial  cells  were examined  for E-selectin  expression  by an ELISA 
assay performed on adherent cells. Data are expressed  as percentage of Ib 
1-induced expression  of E-selectin with respect to mock (mean of tripli- 
cates). -O-,  iclL-lraI; --O-, iclL-lalI. 
The IL-1 system shows an extraordinary level of complexity, 
consisting of two agonists,  two receptors (one of which is 
an inhibitor of IL-1 [2-4]), and a receptor antagonist (of  which 
at least three different molecular forms exist). Although the 
biological significance of the intracellular forms of IL-lra re- 
mains  to be clearly established,  our data indicate  that  two 
different forms of iclL-lra with  different NH2 termini  are 
generated by alternative splicing in response to selected ex- 
ternal stimuli.  The existence of multiple levels of control of 
IL-1 points to the requirement for a tight physiological con- 
trol of the  inflammatory potential  of this  cytokine. 
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